US20220249547A1

US20220249547A1 - Method of preventing covid-19 infection

Info

Publication number: US20220249547A1
Application number: US17/575,276
Authority: US
Inventors: Sabine Hazan
Original assignee: Individual
Current assignee: Individual
Priority date: 2020-03-31
Filing date: 2022-01-13
Publication date: 2022-08-11
Also published as: US11278520B2; US20210299091A1

Abstract

A product for preventing COVID-19 infection in an individual, the product comprising a combination of vitamin C, vitamin D, and zinc. The combination comprises 1,000 mg to 10,000 mg of vitamin C, 3,000 IU to 40,000 IU of vitamin D, and 25 mg to 75 mg of zinc. The combination is administered daily for two or more days for prophylaxis, or the combination is administered weekly over a period of two or more weeks for prophylaxis.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Non-Provisional patent application Ser. No. 17/114,271, titled “Method of Preventing COVID-19 Infection,” filed Dec. 7, 2020, which claims priority to U.S. Provisional Application Ser. No. 63/002,494, titled “Method of Using Vitamin C, Vitamin D, Zinc, and Optionally Hydroxychloroquine, to Prevent COVID-19 Infection,” filed Mar. 31, 2020, and also claims priority to U.S. Provisional Application Ser. No. 63/022,368, titled “Method of Using Vitamin C, Vitamin D, Zinc, and Optionally Hydroxychloroquine, to Prevent COVID-19 Infection,” filed May 8, 2020, the contents of which are incorporated by reference in their entirety.

BACKGROUND

COVID-19 is a novel betacoronavirus that originated in bats in the city of Wuhan, China. This disease has rapidly spread to become a worldwide pandemic. Scientists have identified the molecular structure of the spike glycoproteins on the surface of the virus, which are what allow the virus to “stick” to its target, and in this case the human lung. The virus has a very similar sequence and structure to the coronavirus that causes SARS, with the exception of the receptor binding domain. In this domain there is a loopy, flexible glycyl in place of a rigid prolyl, which allows it to tightly bind to a hydrophobic pocket in the receptor, ACE2.
Thus, there is a significant unmet need for preventing this viral infection.

SUMMARY

The present invention addresses this need. The invention is directed to a method of preventing COVID-19 infection in a healthy individual, the method comprising the steps of:
a) providing the healthy individual;
b) administering, on day 1, 1,000 mg to 10,000 mg of vitamin C, 1,000 mg to 40,000 mg of vitamin D, and 25 mg to 75 mg of zinc;
c) administering daily, on days 2 through 7, 1,000 mg to 10,000 mg of vitamin c and 25 mg to 75 mg of zinc; and
d) repeating steps b) and c) for 1 to 23 weeks.
Optionally, step c) comprises administering daily, on days 2 and 3, 10,000 mg of vitamin c and 50 mg of zinc; and administering daily, on days 4 through 7, 3,000 mg of vitamin c and 50 mg of zinc.
Optionally, step c) comprises assessing the patient for potential adverse events, serious adverse events, and COVID-19 symptoms.
Optionally, steps b) and c) comprise administering selenium, copper and other vitamins that are appropriate supplements for vitamin C, vitamin D or zinc.

DRAWINGS

These and other features, aspects and advantages of the present invention will be better understood with reference to the following description, appended claims, and accompanying drawings where:

FIG. 1 is a flow chart depicting the steps of a first method of preventing infection with COVID-19.

DETAILED DESCRIPTION OF THE INVENTION

The following discussion describes in detail one embodiment of the invention with several variations of that embodiment. This discussion should not be construed, however, as limiting the invention to those particular embodiments. Practitioners skilled in the art will recognize numerous other embodiments as well.
This invention describes a method of triple therapy for preventing a COVID-19 infection.
Definitions
As used herein, the following terms and variations thereof have the meanings given below, unless a different meaning is clearly intended by the context in which such term is used.
The terms “a,” “an,” and “the” and similar referents used herein are to be construed to cover both the singular and the plural unless their usage in context indicates otherwise.
As used in this disclosure, the term “comprise” and variations of the term, such as “comprising” and “comprises,” are not intended to exclude other additives, components, integers, ingredients or steps.
The present invention is directed to a method of preventing COVID-19 infection in an individual. The method comprises administering three different supplements. The supplements comprise:
Vitamin C, Vitamin D, Zinc, and any mixtures thereof.
The length of preventative treatment of the present invention can be as long as necessary. However, regardless of the length of treatment, Vitamin C is provided at 10,000 mg daily for the first three days of treatment, and then 3000 mg daily thereafter. This 10,000 mg of Vitamin C can be broken up into two doses, one taken in the morning and one taken at night.
Vitamin D is provided at 40,000 mg one day every 4 weeks (or however many weeks the preventative treatment lasts). This 40,000 mg of Vitamin D can be broken up into two doses, one taken in the morning and one taken at night.
Zinc is provided at 50 mg per day ongoing, for the length of the preventative treatment. This 50 mg of Zinc can be broken up into two doses, one taken in the morning and one taken at night.
On Day 1 (Week 1), the patient provides verbal informed consent, the patient reviews prior (previous 3 months) and concomitant medications and the patient receives the three different supplements: Vitamin C, Vitamin D, and Zinc. The patient takes 10,000 mg of Vitamin C, 40,000 mg of Vitamin D, and 50 mg of zinc.
On Days 2 and 3 (Week 1), the patient takes 10,000 mg of Vitamin C and 50 mg of zinc daily. This 3,000 mg can be broken up into two 1500 mg doses, one taken in the morning and one taken at night. The patient is called on the phone for assessment for potential adverse events (AE) and serious adverse events (SAE), and any COVID-19 symptoms.
On Days 4-7 (Week 1), the patient takes 3,000 mg of Vitamin C and 50 mg of zinc daily.
On Day 8 (Week 2), the patient takes 3,000 mg of Vitamin C, 40,000 mg of Vitamin D, and 50 mg of zinc.
On Days 9-14 (Week 2), the patient takes 3,000 mg of Vitamin C and 50 mg of zinc daily.
Weeks 3-24 continue with the same protocol identified above for Week 2.
During Weeks 1-23, the patient is called weekly on the phone for assessment for adverse events and serious adverse events, and any COVID-19 symptoms. The list of prior and concomitant medications is also updated.
During Week 24, the patient is called to the clinic for evaluation to include assessment for potential adverse events and serious adverse events, to update the list of prior and concomitant medications, to perform confirmatory COVID-19 testing, and to perform blood testing.
Optionally, Vitamin C dosage can range from 1000mg to 10,000mg per day, Vitamin D dosage can range from 1000 IU to 40000 IU per day, Zinc (the zinc can be any type or form of zinc) dosage can range from 25-75 mg per day. As noted above, all daily doses of Vitamin C, Vitamin D and Zinc can be broken up into two daily doses, wherein one dose is taken in the morning and one dose is taken in the evening. For all protocols provided in this application, when a dosage range is provided, any dosage amount that is included in that range can be administered. Accordingly, the invention is not limited to the dosage ranges disclosed, and includes all dosage amounts contained in those ranges.
The protocol provided in this application can also include selenium, copper and other vitamins that are deemed appropriate supplements for Vitamin C, Vitamin D or Zinc or, to counteract the negative depletion of certain vitamins, like copper or selenium.
Treatment can be for one day or consecutive or repeated in 2 weeks, 1 month, 6 months or 1 year.
The Vitamin C, Vitamin D and Zinc, and mixtures thereof, can be administered orally, in the form pills/lozenges, an aerosolized spray, or a food substance such as a liquid drink or yogurt composition. Optionally, the Vitamin C, Vitamin D and Zinc can be administered in the form of a nasal spray or a topical application, such a lotion or spray for administration on the individual's skin.
Table 1 outlines the schedule of events for this protocol.

TABLE 1

Assessment	Screening (Day 1)	Day 2	Day 3	Day 4	Weeks 1-23	Weeks 24/ET(±4 d)

Informed Consent & Demographics	X
Review of Prior and Concomitant Medications	X
Physical Exam						X
Vitals^a						X
Prescription of vitamin C, vitamin D, and zinc	X
Update list of prior concomitant medications	X				X	X
Ask about AE and SAE		X	X		X	X
Update dose of Vitamin C to 3000 mg daily				X
Evaluation for COVID-19 symptoms					X	X
COVID-19 testing						X
a. Blood draw for future testing^b						X

^aVitals to include height (only at first visit), weight, blood pressure (following 5 minutes sitting), pulse, respiratory rate, temperature, and oxygen saturation.
^bFuture testing will require separate informed consent and can include antibody or cytokine testing.

COVID-19 sample collection period (to be conducted by patient's physician if infection is suspected at any time during the study or after). Nasopharyngeal (NP) and oropharyngeal (OP) swabs will be collected according to CDC protocol—which include synthetic fiber swabs with plastic shafts. The NP swabs are collected by insertion of a swab into the nostril parallel to the palate. The swab is left in place a few seconds to allow it to absorb secretions. The OP swabs are inserted into the oropharynx parallel to the palate, avoiding the tongue. The swab is left in place a few seconds to allow it to absorb secretions. These swabs are immediately placed in sterile tubes with 2-3 mL of viral transport media. The tubes are placed in biohazard bags then boxes and couriered to the local Public Health Lab.
The above protocols can be used to prevent infection with other viruses (not just COVID-19), including other flu viruses.
The above protocols can also be used to treat Autism, Parkinson's, Alzheimer's and other neurological diseases.

EXAMPLES

Example 1: Successful Treatment of COVID-19 Infected Outpatients and Prophylaxis of Immediate Associates

Objective: to successfully treat COVID-19 infected outpatients and prophylaxis of immediate associates.
Procedure: Prospective COVID-19 infected individuals were diagnosed using a Pangea DNA/RNA Shield™ Collection Tube to obtain a nasopharyngeal swab and PCR+ve patients were entered into the study. They were immediately commenced on a 10 day course of Hydroxychloroquine (200 mg, twice a day, for 10 days), Azithromycin extended release (500 mg on day 1, then 250 mg a day for days 9-10), zinc (50 mg a day for days 1-10), Vitamin D (3000 IU a day for days 1-10) and Vitamin C (3000 mg a day for days 1-10). Some individuals lived alone, otherwise immediate partners and family deemed to be most exposed were given a prophylactic which comprised hydroxychloroquine 200 mg twice a day on day 1 only with Zinc, Vitamin C and Vitamin D for given at the same doses as above for days 1-10.
Results: In 11 families a total of 21 family members were identified to be PCR COVID-19 positive index cases and were treated with the above treatment protocol while 22 exposed associates with negative PCR were given the above prophylaxis protocol. This is shown below in Table 24. All 21 index cases were cured of COVID-19 infection as judged by the repeat swab PCR on day 10 and accompanying symptom resolution. None of the 22 highly exposed associates developed COVID-19 infection when retested on day 10 (day 14 in Family 10) in spite of close co-habitation with the infected index cases. TABLE 2: Results from families received 10-day course of daily HCQ (200 mg bd), AZ extended release (500 mg day 1, then 250 mg), zinc (50 mg), Vitamin D (3000 IU) and Vitamin C (3000 mg)

TABLE 2

				After treating
		Age		with HAZDPAC	After treating
		(years)-		Cured/PCR test	ZINCD+H
	Patient/s	sex of the	Comorbidities	positive/negative/	family member
Family	treated	patient	of the patients	other symptoms	prophylaxed

#1	1	23-male	Asthma	Negative	Parents
				PCR-day 10	overweight,
					diabetes, father
					with heart
					disease never
					got the disease
#2	3	60-male	Asthma	All 3 patients	Mother didn't
		(father)		cured	get the virus
		18-male
		(son)
		16-female
		(daughter)
#3	1	40-female	Avoided	Sever multiple	Husband did not
			intubation by	symptoms	turn positive
			leaving hospital	resolved at home
#4	2	78-male	BCG+COPD,	Both cured	Daughter,
		77-female	diabetes, heart		son-in-law and 2
			disease (heart		grandkids didn't
			surgery month		catch the virus
			prior
			Pacemaker,
			BCG
#5	3	56-male	Unable to	Started treatment	Wife never
		27-male	eat or drink	on day 10, Sever	got the disease
		24-female	Asthma	symptoms resolved
				Cured
#6	1	56-female		Admitted to	Husband never
				hospital-	got the disease
				sent home, as two
				kids were sick
				with fever. All
				recovered with
				vitamins
#7	1	44-female		Cured,	Husband and
				autoimmune	4 kids never
				issues started	got the disease
#8	3	52-female	Lupus	Cured	Boyfriend (54 y)
		53-male	Severe asthma	Cured	with Diabetes,
		19-male		Cured	son (18) and
					daughter (16)
					never got the
					disease
#9	2	45-female		Both cured from	Husband and
		16-male		severe symptoms	daughter never
				of cough and fever	got the disease
#10	2	44-male		Cured from loss of	Mother (50 y)
		25-female		smell, fever, cough	never got
		21-female		Cured	the disease
				Partially treated
				with HAZDPAC-
				slowly turned −ve
#11	1	33-female	No	ICU nurse	Boyfriend never
				recovered	got the disease

Apart from the families a further 11 single infected individuals found to be swab PCR positive were treated with the above treatment protocol. This is shown below in Table 3. All were also successfully cured of the infection.

TABLE 3

	Age (years)-	Comorbidities/	After treating
	sex of	symptoms	with HAZDPAC
Patient	the patient	of the patients	Cured/not

#1	44-female	Asthma	Cured
	(no BCG
	in childhood)
#2	81-male	Diarrhea	Cured
#3	52-female	Fever	Cured
#4	66-male	Valve surgery	Cured
#5	29-female	Asthma	Cured
	(no BCG
	in childhood)
#6	50-female	Auto immune thyroiditis,	Cured
		sever cough and fever
#7	43-male	Cough, desaturation of oxygen	Cured
#8	53-male	Diarrhea, cough, fever,	Cured
		desaturation of oxygen
#9	44-female	Autoimmune history, fever,	Cured
		increase heart rate
#10	44-female	Pneumothorax discharged	Cured
		from ICU with COVID-19
#11	43-male	Fever +ve Covid-19 PCR	Cured

A further 9 individuals recently closely exposed to Covid-19 infected persons were given the prophylaxis protocol outlined above. The prophylactic worked very well with no exposed person acquiring the infection. This is shown in Table 4.

TABLE 4

	Age (years) &	After treating
Individual	details of the individual	with ZINCD+H

#1	Mother of 16 year old	Prophylaxed and
	child who had COVID-19	never got the disease
#2	24-female, ICU nurse-	Prophylaxed and
	multiple exposures	never got the disease
#3	47-male, cardiologist exposed	Prophylaxed and
	to +ve patients	never got the disease
#4	70-male medical director	Prophylaxed and
	of a hospital (exposed to	never got the disease
	numerous doctors with COVID-19)
#5	55-male anaesthesiologist	Prophylaxed and
	(intubates COVID-19 patients)	never got the disease
#6	55-ICU nurse (worked on	Prophylaxed and
	COVID-19 floor)	never got the disease
#7	40-ICU nurse many	Prophylaxed and
	Covid-19 patients	never got the disease
#8	53-Doctor with pancreatitis	Prophylaxed and
		never got the disease
#9	28-Paramedic-healthy	Prophylaxed and
		never got the disease

Discussion: It was demonstrated that a 10 day combination of hydroxychloroquine, azithromycin (for 5 days only), zinc with vitamin D and vitamin C, can result in uniform cure of COVID-19 infection when used in an outpatient population. The prophylaxis treatment noted above for those closely exposed to proven, infected patients can completely prevent spread of COVID-19. This combination of test-and-treat permits abolishing of new outbreaks of infection such as a ‘next wave’—by avoiding quarantine to treat the infected and give prophylactics to surrounding staff and family.
In conclusion, this is an effective anti-Covid-19 therapy as well as an effective prophylactic combination capable of arresting the spread of coronavirus infection throughout the community. This is achieved by treating the index case and the surrounding associates of the patient as early as possible after infection is identified and then treating the people they live with and close associates.
Having thus described the invention, it should be apparent that numerous structural modifications and adaptations may be resorted to without departing from the scope and fair meaning of the instant invention as set forth herein above and described herein below by the claims.

Claims

What is claimed is:

1. A product for preventing COVID-19 infection in an individual, the product comprising a combination of:

a) vitamin C;

b) vitamin D; and

c) zinc.

2. The product of claim 1, wherein the combination is administered weekly over a period of two or more weeks for prophylaxis.

3. The product of claim 1, wherein the combination is administered daily over a period of two or more days for prophylaxis.

4. The product of claim 1, wherein the combination comprises:

a) 1,000 mg to 10,000 mg of vitamin C;

b) 3,000 IU to 40,000 IU of vitamin D; and

c) 25 mg to 75 mg of zinc;

wherein the combination is administered daily for two or more days for prophylaxis.

5. The product of claim 4, wherein the combination is administered weekly over a period of two or more weeks for prophylaxis.

6. The product of claim 4, wherein the combination is administered daily over a period of two or more days for prophylaxis.

7. The product of claim 1, wherein the combination comprises:

a) 3,000 mg of vitamin C;

b) 3,000 mg of vitamin D; and

c) 50 mg of zinc.

8. The product of claim 4, wherein the combination comprises:

b) 3,000 mg of vitamin C;

c) 3,000 mg of vitamin D; and

d) 50 mg of zinc.